Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Bemcentinib + Ceritinib |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bemcentinib | BGB 324|BGB-324|BGB324|R428|R-428 | AXL Inhibitor 29 | Bemcentinib (BGB-324) is a small molecule inhibitor of Axl, which inhibits tumor growth and may overcome EMT-mediated acquired drug resistance (PMID: 20145120, PMID: 31134766). | |
Ceritinib | Zykadia | LDK378 | ALK Inhibitor 31 ROS1 Inhibitor 20 | Zykadia (ceritinib) inhibits ALK, including ALK mutations and fusions, and has additional activity against ROS1 fusions, potentially resulting in decreased tumor cell growth (PMID: 25322323, PMID: 26372962). Zykadia (ceritinib) is FDA approved for ALK-positive (rearrangements and fusions) metastatic non-small cell lung cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ALK R1275Q AXL pos | neuroblastoma | sensitive | Bemcentinib + Ceritinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Bemcentinib (BGB-324) to treatment with Zykadia (ceritinib) increased Zykadia (ceritinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK R1275Q in culture (PMID: 25450694). | 25450694 |
ALK F1174L AXL pos | neuroblastoma | sensitive | Bemcentinib + Ceritinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Bemcentinib (BGB-324) to treatment with Zykadia (ceritinib) increased Zykadia (ceritinib)-induced apoptosis in an AXL-expressing neuroblastoma cell line harboring ALK F1174L in culture (PMID: 25450694). | 25450694 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|